Health TechnologyApril 26, 2026·4 min read
By the CIRRUS Editorial Team — how we write and source this
Fecal microbiota transplant: the one FDA-approved use and the many unapproved ones under study
FMT has a specific, well-established medical application and a much larger, still-experimental research frontier that's easy to conflate.
Fecal microbiota transplant — transferring processed stool from a screened donor to a recipient, typically via colonoscopy, enema, or oral capsule — has strong, well-established evidence and formal FDA-approved products specifically for recurrent Clostridioides difficile infection that hasn't responded to standard antibiotic treatment, where cure rates in trials have been notably high compared to further antibiotic courses.
Beyond this specific approved use, FMT is being actively researched for a range of other conditions — inflammatory bowel disease, certain metabolic conditions, and some neurological and psychiatric conditions under the gut-brain axis research umbrella — but evidence for these applications remains considerably earlier stage, with more mixed and preliminary results than the C. diff use case, and none currently have FDA-approved indications.
The FDA has specifically warned about unregulated FMT products and unsupervised use outside clinical settings, given documented cases of serious infection transmission from inadequately screened donor material — a real risk that underscores why FMT for its approved use, and any experimental use, should go through a proper clinical setting with donor screening protocols rather than unregulated sourcing.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.